CHA2DS2-VASc had better discrimination than CHADS2 for predicting risk for thromboembolism in atrial fibrillation

Annals of Internal Medicine

Volumn 154, Issue 10, 2011, Pages

  Cairns, John A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; HEPARIN DERIVATIVE;

CAUSE OF DEATH; COMPARATIVE ANATOMY; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HOSPITALIZATION; HUMAN; NOTE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; STROKE; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

EID: 79956341734     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-154-10-201105170-02013     Document Type: Note

References (3)

1. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-2429.
2. Cairns JA, Connolly S, McMurtry S, et al. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol. 2011;27:74-90.
3. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-817.